Biogen, Elan report cases of brain disease
Two multiple-sclerosis patients treated with Biogen Idec Inc.'s drug Tysabri contracted a potentially deadly brain infection. The news casts a cloud over the revival of the medicine, which was already withdrawn once over safety concerns. Biogen said it had no plans to recall the drug again or restrict its use. The company said that the two patients who contracted the ailment, progressive multifocal leukoencephalopathy, or PML, are alive.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Healthcare Costs Start With What We Eat
- IOM Identifies GME Problems, Calls for Finance Changes
- Hospitals Likely to Outsource ICD-10 at Launch
- Revenue Cycles Get a Boost from Simple JPEG Files
- Anatomy of 3 Health System Rebranding Efforts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL